文献速递类风湿关节炎

阿托伐他汀对高风险人群类风湿关节炎预防作用:STAPRA试验提前终止结果

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial.
PubMed 文献 · RMD Open · 2021-01-01

STAPRA随机双盲安慰剂对照试验旨在评估阿托伐他汀能否预防高风险人群发生关节炎,计划纳入220例但仅随机62例即因入组率低提前终止。中位随访14个月,阿托伐他汀组9/31(29%)发生关节炎,安慰剂组6/31(19%),HR 1.40(95%CI 0.50-3.95),未显示保护作用。

要点

  • STAPRA试验因入组率低提前终止,仅分析62例高风险个体。
  • 阿托伐他汀组关节炎发生率29%,安慰剂组19%,HR 1.40(95%CI 0.50-3.95)。
  • 未证实阿托伐他汀对高风险人群关节炎发展有保护作用。

核心结论

  • 在少量高风险随机个体中,未证明阿托伐他汀对关节炎发展具有保护作用。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,计划样本量220例,因入组率低提前终止,实际分析62例随机个体。

主要发现

  • 阿托伐他汀组9/31(29%)发生关节炎,安慰剂组6/31(19%),HR 1.40(95%CI 0.50-3.95)。

关键数值与推荐

  • 纳入标准:有ACPA>3×ULN或ACPA阳性且类风湿因子阳性的关节痛患者,无关节炎病史或当前关节炎。
  • 干预:阿托伐他汀40 mg每日一次或安慰剂,持续3年。
  • 主要终点:临床关节炎。

临床怎么用

  • 不推荐使用阿托伐他汀用于高风险人群的类风湿关节炎一级预防。
  • 开展类风湿关节炎预防试验需关注并解决参与者不愿参加这一主要障碍。

局限性

  • 试验因入组率低提前终止,样本量小(62例),随访时间短(中位14个月),统计效能不足。
  • 低入组率主要因不愿意参与,可能影响结果外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Persons at high risk of rheumatoid arthritis (RA) might benefit from a low-risk pharmacological intervention aimed at primary prevention. Previous studies demonstrated disease-modifying effects of statins in patients with RA as well as an association between statin use and a decreased risk of RA development. A randomised, double-blind, placebo-controlled trial investigated whether atorvastatin could prevent arthritis development in high-risk individuals. METHODS: Arthralgia patients with anticitrullinated protein antibody (ACPA) >3 xULN or ACPA and rheumatoid factor, without (a history of) arthritis, were randomised to receive atorvastatin 40 mg daily or placebo for 3 years. The calculated sample size was 220 participants. The primary endpoint was clinical arthritis. Cox regression analysis was used to determine the effect of atorvastatin on arthritis development. RESULTS: Due to a low inclusion rate, mainly because of an unwillingness to participate, the trial was prematurely stopped. Data of the 62 randomised individuals were analysed. Median follow-up was 14 (inner quartiles 6-35) months. Fifteen individuals (24%) developed arthritis: 9/31 (29%) in the atorvastatin group; 6/31 (19%) in the placebo group: HR 1.40, 95% CI 0.50 to 3.95. CONCLUSIONS: In this small set of randomised high-risk individuals, we did not demonstrate a protective effect of atorvastatin on arthritis development. The main reason for the low inclusion was unwillingness to participate; this may also impede other RA prevention trials. Further research to investigate and solve barriers for prevention trial participation is needed.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. van Boheemen L, Turk S, Beers-Tas MV, et al. Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial. RMD Open. 2021. PMID: 33685928. doi:10.1136/rmdopen-2021-001591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。